Development Pipelines

Polysaccharide-based carriers can not only enhance the solubility of poorly water-soluble drugs but can also generate new types of first in class of new drugs and controlled-release formulations, long-acting formulations, or extended-releasing formulations for poorly water-soluble drugs.  In addition, our technology platform GlycoTDSTM  has "high tunability" to a variety of drug payloads and the capability to combine active tumor targeting using tumor receptor targeting ligands or macropinocytosis pathway with passive tumor targeting using supra-molecular polymers EPR effects. This endows polysaccharide-based drug conjugates with dual targeting effects that can effectively attack a wide range of tumor targets. 

The GlycoTDSTM  platform may address currently challenges and bottlenecks using monoclonal antibodies (mAbs) and small molecules.

.  

Compatible spaces and application potentials of  our platform GlycoTDSTM 

Drug loading compatible space of polysaccharide-based drug delivery system platform

1) Small molecular drugs; 2)Peptide drugs; 3) Small molecular nucleic acid drug for antisense oligonucleotide(ASO), siRNA, shRNA, etc.; 4)Proteolysis targeting chimeras (PROTACs)for targeted protein degradation; 5)Inorganic metal drugs.

Targeting ligand compatible space of polysaccharide-based drug delivery system platform

1) Lipid clusters; 2) Sugar unit clusters; 3)Peptides and derivatives; 4)Aptamers; 5)Antibody Fab fragments.